Interstitial Lung Disease

Idiopathic pulmonary fibrosis (IPF) is a progressive, deadly disorder that has no proven therapy.

Dr. Nathan Sandbo leads a research team seeking to elucidate the molecular pathways which mediate fibrotic lung diseases, such as IPF, to help identify new targets for therapy. Areas of ongoing investigations include: elucidation of signaling pathways that mediate myofibroblast differentiation and function and the role of certain transcription factors in fibroblast activation.

Dr. Keith Meyer is leading a number of multi-center clinical trials that are evaluating novel drug therapies for IPF.